Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 18/20 | 0.51 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.44 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.40 |
| ▸ | P2RX3 | P56373 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2125901 | 0.95 | S1PR1 (0.53) | S1PR1S1PR3S1PR5 | |
| SCHEMBL2124261 | 0.91 | S1PR1 (0.59) | S1PR1S1PR3S1PR5 | |
| SCHEMBL2123243 | 0.90 | S1PR1 (0.43) | S1PR1S1PR5P2RX3 | |
| SCHEMBL2132203 | 0.87 | S1PR1 (0.62) | S1PR1S1PR3S1PR5 | |
| SCHEMBL2123838 | 0.86 | S1PR1 (0.44) | S1PR1S1PR3S1PR5P2RX3 | |
| SCHEMBL2125570 | 0.85 | S1PR1 (0.45) | S1PR1S1PR5P2RX3 | |
| SCHEMBL2126660 | 0.84 | S1PR1 (0.59) | S1PR1S1PR3S1PR5 | |
| SCHEMBL2124802 | 0.82 | S1PR1 (0.42) | S1PR1S1PR5 | |
| SCHEMBL2133890 | 0.81 | S1PR1 (0.47) | S1PR1S1PR3S1PR5P2RX3 | |
| SCHEMBL2125905 | 0.81 | S1PR1 (0.50) | S1PR1S1PR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2443115-B1 | Pyrrolo-pyridine derivatives useful to treat diseases connected to S1P1 receptors | GLAXO GROUP LTD (GB) | 2013-08-28 | — | — | EP | disclosed |
| EP-2443115-B1 | Pyrrolo-pyridine derivatives useful to treat diseases connected to S1P1 receptors | GLAXO GROUP LTD (GB) | 2013-08-28 | — | — | EP | disclosed |
| US-20120101123-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2012-04-26 | — | — | US | disclosed |
| US-20120101123-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2012-04-26 | — | — | US | disclosed |
| US-20120101123-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2012-04-26 | — | — | US | disclosed |
| EP-2443115-A1 | COMPOUNDS | Glaxo Group Limited (GB) | 2012-04-25 | — | — | EP | disclosed |
| WO-2010145201-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2010-12-23 | — | — | WO | disclosed |
| WO-2010145201-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2010-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120101123-A1 | COMPOUNDS | CYP11B2, CYP11B1, GPR119 | S1PR1 1075/4885S1PR3 1079/4885S1PR5 930/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.